Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Funding, Award

Sinopia Secures Grant Funding from the National Institute of General Medical Sciences to Advance Proprietary Metabolomics Platform


Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, announced today that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences (NIGMS) to advance its computational drug discovery LEarn And DiScover (LEADStm) platform and explore applications in oncology and immunology.

"We remain focused on building an integrated metabolomics-based, high-throughput screening, and artificial intelligence and machine learning drug discovery platform that can identify novel targets and therapeutic candidates," said Aarash Bordbar, Ph.D., Co-founder and Chief Technology Officer of Sinopia Biosciences. "Our preliminary studies showcase the unique value of using large scale metabolomics datasets for drug discovery. Funding from the National Institute of General Medical Sciences supports our effort in further developing novel algorithms to more effectively analyze the proprietary metabolomics datasets we have generated. This research funding will also allow us to explore new and important therapeutic areas using our platform in oncology and immunology."

Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R43GM154585. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Sinopia Biosciences

Sinopia Biosciences, Inc. is a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform. Sinopia's discovery platform combines high-throughput omics data, machine learning, and network biology. Sinopia is headquartered at JLABS San Diego. For more information, please visit www.sinopiabio.com/.


These press releases may also interest you

at 18:39
The Hughes Holden Foundation, a nonprofit organization committed to supporting initiatives that improve mental healthcare to marginalized and underserved communities in the U.S., is proud to announce a significant gift to Columbia University....

at 18:21
Product Creation Studio (PCS), a premier provider of engineering and design services, is excited to announce a new partnership with PatchClamp Medtech Inc. (PMI). This collaboration focuses on developing PatchClamp's novel dural repair graft...

at 18:20
The global wearable patch market  size is estimated to grow by USD 7.11 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 13.26%  during the forecast period.  ...

at 18:00
The global flow diversion aneurysm treatment market size is estimated to grow by USD 2.43 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  9.34%  during the forecast period. The flow diversion aneurysm...

at 18:00
The Neighbourhood Pharmacy Association of Canada (Neighbourhood Pharmacies) is honoured to present the Len Marks Pharmacy Advancement Award to the Coutu Family and Distinguished Partner of the Year Award to Mike Dutton of Pharmascience Canada. Sandra...

at 17:50
The global rehabilitation robots market  size is estimated to grow by USD 4648 mn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  39.98%  during the forecast period.  The rehabilitation robots market is surging,...



News published on and distributed by: